New data presented at the British Society for Allergy and Clinical Immunology (BSACI) annual meeting demonstrate that Grazax® is the first tablet treatment to provide sustained disease control in patients with grass pollen rhinoconjunctivitis (hay fever) after the treatment period ended. This is the first time disease modification by sublingual allergy immunotherapy tablets has been achieved; effectively re-setting the immune system to reduce future allergic reactions to grass pollen.
generic viagra online
A health care reform proposal that would allow employers and insurers to give large discounts to employees who lose weight or lower their cholesterol is facing push back from several groups worried about premium disparities, Kaiser Health News reports.